Welcome to our dedicated page for CorMedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on CorMedix stock.
CorMedix Inc. (Nasdaq: CRMD), headquartered in Bridgewater, NJ, is a biopharmaceutical company dedicated to the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. The company's flagship product, DefenCath®, is targeted towards reducing the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter.
Recently, CorMedix announced its financial results for the fourth quarter and full year ended December 31, 2023, during a conference call held on March 12, 2024. The company showcased significant advancements in their product pipeline and continued efforts to expand the market reach of DefenCath®. This includes ongoing clinical trials and strategic partnerships aimed at enhancing patient safety and treatment efficacy.
DefenCath®, which combines taurolidine and heparin, has been pivotal in addressing the critical need for infection control in hemodialysis patients. The product has shown promising results in reducing bloodstream infections and is poised to make a substantial impact in the healthcare sector. CorMedix remains committed to research and development, with an emphasis on innovation and quality.
For more detailed information about DefenCath®, including safety information, prescribing guidelines, and potential adverse effects, professionals and patients are encouraged to review the full prescribing information available on the company's website.
CorMedix's financial health remains robust, bolstered by strategic investments and a clear focus on growth and sustainability. The company continues to engage with investors and stakeholders through transparent communication and regular updates on their progress.
For latest updates and detailed news about CorMedix Inc., investors and interested parties can visit the company's website and review recent press releases and financial reports.
CorMedix Inc. (Nasdaq: CRMD) has announced the commercialization of DefenCath® (taurolidine and heparin) for outpatient dialysis centers and vascular access clinics. This launch, effective from July 1st, aligns with the Centers for Medicare & Medicaid Services (CMS) reimbursement for outpatient use.
DefenCath, approved by the FDA under the Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, initially launched for inpatient settings on April 15, 2024. The product is designed to reduce catheter-related bloodstream infections (CRBSI) in adults undergoing chronic hemodialysis through a central venous catheter.
CorMedix has begun shipping orders to dialysis operators, with additional customer agreements expected soon. The CEO, Joseph Todisco, expressed optimism about expanding access and the effective rollout by customers.
CorMedix (NASDAQ: CRMD) has received supportive feedback from the FDA regarding its plans to expand the use of DefenCath to adult Total Parenteral Nutrition (TPN) patients. The company plans to submit a complete clinical protocol by the third quarter of 2024 and aims to start the program by year-end. The FDA also requires a pediatric study under the Pediatric Research Equity Act. An independent market assessment shows a critical unmet need for DefenCath in TPN patients, with an estimated CLABSI rate over 25% and an addressable market of 5 million yearly infusions. Further details will be shared in CorMedix's Q2 earnings call in August.
CorMedix announced that CMS has granted pass-through status to DefenCath under the Out-Patient Prospective Payment System (OPPS). This status allows for separate Medicare Part B payments for DefenCath for at least two years, and up to three years, in outpatient settings. DefenCath, a combination of taurolidine and heparin, is used to reduce catheter-related bloodstream infections (CRBSI) in chronic hemodialysis patients using central venous catheters. The company estimates around 100,000 HD-CVC placements annually, highlighting the importance of reimbursement for DefenCath to prevent CRBSIs. However, DefenCath is contraindicated in patients with heparin-induced thrombocytopenia or hypersensitivity to any of its components.
CorMedix (Nasdaq: CRMD) announced a multi-year commercial supply contract with a top-tier midsized dialysis provider for the supply of DefenCath® (taurolidine and heparin). Approved under the LPAD pathway on November 15, 2023, DefenCath® started commercialization in inpatient settings on April 15 and will begin in outpatient dialysis clinics in July. The agreement covers over 500 dialysis facilities, providing thousands of patients access to the infection-reducing product. CEO Joseph Todisco emphasized the importance of broad patient access and the company's commitment to innovation and infection reduction.
CorMedix Inc. (Nasdaq: CRMD) is set to participate in two upcoming investor conferences, the JMP Securities Life Sciences Conference on May 13-14, 2024, and the RBC Capital Markets Global Healthcare Conference on May 14-15, 2024. Management will engage in fireside chats and investor meetings during these events, with details provided for each. The events will be webcasted, and replays will be available on the company's investor relations website.
CorMedix Inc. reported financial results for Q1 2024, highlighting a net loss of $14.5 million. The company successfully launched DefenCath® and secured a commercial supply contract with ARC Dialysis. CMS approved a new HCPCS code for DefenCath, qualifying for TDAPA. The FDA granted a Type C meeting to discuss development plans. The company remains financially stable with $58.6 million in cash and short-term investments.
CorMedix Inc. (Nasdaq: CRMD) will report its financial results for the first quarter of 2024 on May 9, 2024. The company focuses on developing therapeutic products for life-threatening diseases. A corporate update conference call will follow the release.
FAQ
What does CorMedix Inc. specialize in?
What is DefenCath®?
Where is CorMedix Inc. headquartered?
How did CorMedix Inc. perform in the fourth quarter of 2023?
Who can use DefenCath®?
What are the potential side effects of DefenCath®?
How can safety concerns about DefenCath® be reported?
What recent events did CorMedix Inc. announce?
Who is the investor contact for CorMedix Inc.?
Where can I find more detailed information about DefenCath®?
